Beta-blockers, diabetes, and hypoglycemia: risky business?
Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucker, RI 02860, USA.
P D
PD
Levinson
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001262:Atenolol / Q000627:therapeutic use; D002216:Captopril / Q000627:therapeutic use; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced* / Q000175:diagnosis / Q000209:etiology; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001262:Atenolol; D002216:Captopril